CMPS:US
$4.30
10.825%

COMPASS Pathways Plc
News & Events

Last updated: Jul 20, 2025, 2:04 PM ET

  1. Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

    Business Wire JUL 10, 2025 4:00 PM EDT
    Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient ac...
    READ ARTICLE
  2. Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

    GlobeNewswire JUL 1, 2025 9:50 AM EDT
    PALM BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - ...
    READ ARTICLE
  3. Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

    Business Wire JUN 23, 2025 6:30 AM EDT
    A single administration of COMP360 demonstrated a highly statistically significant and clinically...
    READ ARTICLE
  4. Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

    Business Wire MAY 14, 2025 6:30 AM EDT
    Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient ac...
    READ ARTICLE
  5. Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

    Business Wire MAY 8, 2025 6:30 AM EDT
    Highlights: 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resi...
    READ ARTICLE
  6. Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

    Business Wire APR 29, 2025 6:30 AM EDT
    Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient ac...
    READ ARTICLE
  7. Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

    Business Wire APR 28, 2025 6:30 AM EDT
    Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pat...
    READ ARTICLE
  8. Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

    Business Wire APR 22, 2025 6:00 AM EDT
    Highlights: Participants received a single dose of either 25 mg of COMP360 or placebo O...
    READ ARTICLE
  9. Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

    Business Wire MAR 26, 2025 6:30 AM EDT
    Highlights: Screening closed for all sites and final participants being scheduled for d...
    READ ARTICLE
  10. Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

    Business Wire MAR 18, 2025 6:30 AM EDT
    Highlights: 52-week observational follow-up study from Phase 2b reveals single 25 mg CO...
    READ ARTICLE

Upcoming Events

Get notified of COMPASS Pathways Plc’s latest announcements, news, and event dates.
  • Upcoming earnings announcement (Unconfirmed)

    Jul 31, 2025
  • Upcoming dividend payout

    Not Available
  • Upcoming stock splits

    Not Available